Plasma LDH: A specific biomarker for lung affectation in COVID-19?

Link to article at PubMed

Pract Lab Med. 2021 Apr 21:e00226. doi: 10.1016/j.plabm.2021.e00226. Online ahead of print.


OBJECTIVES: We aimed to determine whether the plasma profile of lactate dehydrogenase (LDH) isoenzymes is altered in patients with COVID-19, and whether this is attributable to a specific release of LDH-3, the main LDH isoenzyme expressed in lungs.

DESIGN: and Methods: We collected fresh plasma aliquots from 17 patients (LDH range, 281 to 822 U/L) and seven controls (LDH < 230 U/L). In-gel relative activity of the different LDH isoenzymes was determined by electrophoresis and densitometric analysis.

RESULTS: Despite the expected higher total LDH activity levels in patients (p<0.001), the in-gel relative activities of LDH isoenzymes did not differ between patients and controls (all p>0.05). We found no correlation between total plasma LDH activity and the in-gel relative activities of the different LDH isoenzymes, including LDH-3. Likewise, there was no correlation between LDH-3 and various routine haematological and serum parameters that have been previously reported to be altered in COVID-19 (such as lymphocyte count, albumin, alanine and aspartate aminotransferase, creatinine, C-reactive protein, or ferritin).

CONCLUSIONS: Our findings suggest that elevation of plasma LDH activity in patients with COVID-19 is not associated to a specific release of LDH-3 into the bloodstream, and do not support the use of LDH as a specific biomarker for lung affectation in patients with COVID-19.

PMID:33898686 | PMC:PMC8058053 | DOI:10.1016/j.plabm.2021.e00226

Leave a Reply

Your email address will not be published. Required fields are marked *